A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency
An Open-label, Multicentre Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of AEB1102 in Patients With Arginase 1 Deficiency
The purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Porto, Portugal
- Centro Hospitalar S. Joao
-
-
-
-
-
London, United Kingdom
- Great Ormond Street Hospital
-
-
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Florida
-
Gainsville, Florida, United States, 32610
- University of Florida
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
Dallas, Texas, United States, 75390
- UTSW
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Complete treatment in Study CAEB1102-101A without experiencing any clinically significant adverse event or other unmanageable drug toxicity that would preclude continued dosing
- Confirmation by the Investigator and the Sponsor determine that it is acceptable for the patient to continue dosing with AEB1102
- If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment
- If sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration
- Patient or legal guardian is able and willing to provide written informed consent and where required assent, and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification), prior to any screening procedures
Exclusion Criteria:
1. Clinically significant concurrent disease, serious intercurrent illness, or other extenuating circumstances
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: pegzilarginase (AEB1102)
Each patient may receive pegzilarginase administered IV or SC for up to 4 years. |
modified human arginase I
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants With Treatment-related Adverse Events
Time Frame: From start of study up to 262 weeks
|
From start of study up to 262 weeks
|
|
Number of Participants With Anti-pegzilarginase and Anti-PEG Antibodies
Time Frame: From start of study up to 262 weeks
|
From start of study up to 262 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma Arginine Levels
Time Frame: From start of study up to 240 weeks
|
Change in plasma arginine concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (Argininic Acid)
Time Frame: From start of study up to 240 weeks
|
Change in plasma argininic acid concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (Guanidinoacetic Acid)
Time Frame: From start of study up to 240 weeks
|
Change in plasma guanidinoacetic acid concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (α-keto-δ-guanidinovaleric Acid)
Time Frame: From start of study up to 240 weeks
|
Change in plasma α-keto-δ-guanidinovaleric acid concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (α-N-acetylarginine)
Time Frame: From start of study up to 240 weeks
|
Change in plasma α-N-acetylarginine concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Six-Minute Walk Test (6MWT)
Time Frame: From start of study up to 262 weeks
|
Change in 6MWT distance from study Baseline |
From start of study up to 262 weeks
|
|
Gross Motor Function Measure (GMFM) Part D
Time Frame: From start of study up to 262 weeks
|
Change from study Baseline. The GMFM-D evaluates the patient's ability to stand via assessment of 13 activities, each of which is scored on a scale of 0 to 3, with a scale range of 0-39 points. An increase in GMFM-D score indicates improvement in standing. |
From start of study up to 262 weeks
|
|
Gross Motor Function Measure (GMFM) Part E
Time Frame: From start of study up to 262 weeks
|
Change from study Baseline. The GMFM-E evaluates a subject's ability to walk, run, and jump via assessment of 24 activities, each of which is scored on a scale of 0 to 3, , with a scale range of 0-72. A higher GMFM-E score indicates greater ability, with increasing scores indicating improvement in walking, running, and jumping. |
From start of study up to 262 weeks
|
|
Modified Ashworth Scale (MAS)
Time Frame: From start of study up to 262 weeks
|
Spasticity improvement for lower body muscle groups based on MAS from study Baseline. The MAS is used to measure the resistance to passive movement about a joint due to spasticity using a 6-point scoring scale with possible values of 0, 1, 1+ (scored as 1.5), 2, 3, and 4, where 0 is no increase in muscle tone (no spasticity) and 4 is affected part(s) rigid in flexion or extension (total rigidity). Thus, a decrease in MAS score indicates improvement in spasticity. |
From start of study up to 262 weeks
|
|
Berg Balance Scale (BBS)
Time Frame: From start of study up to 262 weeks
|
Change from study Baseline. The BBS, a measure of balance, utilizes a 5-point scoring scale of 0 (indicating the lowest level of function) to 4 (indicating the highest level of function) for 14 tasks, giving a scale range of 0-56, with a higher score representing better balance. |
From start of study up to 262 weeks
|
|
Purdue Pegboard Test (Dominant Hand)
Time Frame: From start of study up to 262 weeks
|
Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average. |
From start of study up to 262 weeks
|
|
Purdue Pegboard Test (Non-dominant Hand)
Time Frame: From start of study up to 262 weeks
|
Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average. |
From start of study up to 262 weeks
|
|
Number of Participants With Hyperammonemic Episodes
Time Frame: From study start up to 262 weeks
|
Hyperammonemic episodes" are defined as either an AE for which an Investigator observed symptoms considered to be consistent with a "hyperammonemic episode", or an AE in a patient meeting all 3 of the following criteria: 1. Confirmed ammonia level ≥100 μM, 2. One or more symptoms related to hyperammonemia, 3. Requiring hospitalization or emergency room management. |
From study start up to 262 weeks
|
|
Number of Participants With Seizures
Time Frame: From study start up to 262 weeks
|
From study start up to 262 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Mattias Rudebeck, PhD MSc BMedSc, Immedica Pharma AB
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Brain Diseases, Metabolic, Inborn
- Brain Diseases, Metabolic
- Amino Acid Metabolism, Inborn Errors
- Urea Cycle Disorders, Inborn
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Hyperargininemia
Other Study ID Numbers
Other Study ID Numbers
- CAEB1102-102A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.